Afatinib in advanced NSCLC: a profile of its use

Afatinib [Giotrif(®) (EU); Gilotrif(®) (USA)] is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases that provides an important first-line treatment option for advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Deeks, Emma D., Keating, Gillian M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Adis Drug Q&A
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840214/
https://www.ncbi.nlm.nih.gov/pubmed/29540977
http://dx.doi.org/10.1007/s40267-018-0482-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840214/
https://www.ncbi.nlm.nih.gov/pubmed/29540977
http://dx.doi.org/10.1007/s40267-018-0482-6

Ejemplares similares